未脾切除的持续性或慢性原发性免疫性血小板减少症成人感染:危险因素与疫苗接种效果
基于法国FAITH队列(n=1805)的全国药物流行病学研究,评估未脾切除的持续性或慢性原发性免疫性血小板减少症成人中严重和非严重感染的危险因素及肺炎球菌和流感疫苗的保护作用。慢性肺病、糖皮质激素和利妥昔单抗是感染的主要危险因素,而肺炎球菌和流感疫苗对严重和非严重感染均有保护作用。
要点
- 慢性肺病、糖皮质激素和利妥昔单抗是感染的主要危险因素。
- 肺炎球菌疫苗对严重和非严重感染均有保护作用。
- 流感疫苗对严重和非严重感染均有保护作用。
核心结论
- 慢性肺病、糖皮质激素和利妥昔单抗是感染的主要危险因素,而肺炎球菌和流感疫苗对严重和非严重感染均有保护作用。
研究设计与样本
- 研究人群为2009-2012年FAITH队列(n=1805),即法国全国医疗保险数据库(SNIIRAM)中所有接受治疗超过3个月的新诊断原发性免疫性血小板减少症成人。
主要发现
- 严重感染发生率为6.3/100患者年(95%CI 5.4-7.4),其中42.8%为下呼吸道感染;非严重感染发生率为100.5/100患者年(95%CI 95.0-106.3)。
- 多因素分析中,年龄增长和慢性肺病与严重感染和非严重感染发生均相关。
- 糖皮质激素和利妥昔单抗对严重感染的HR分别为3.83(95%CI 2.76-5.31)和2.60(95%CI 1.67-4.03)。
- 糖皮质激素和利妥昔单抗对非严重感染的HR分别为2.46(95%CI 2.19-2.76)和1.49(95%CI 1.28-1.74)。
- 肺炎球菌疫苗对严重感染和非严重感染的保护效应分别为0.38(95%CI 0.20-0.73)和0.52(95%CI 0.43-0.65)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Essentials The risk factors for infection in immune thrombocytopenia are not well known. We conducted a national pharmacoepidemiological study. Pulmonary disease, corticosteroids and rituximab were the main risk factors for infections. Pneumococcal and influenza vaccines were protective against infections. SUMMARY: Introduction Risk factors for infection and protective effect of vaccines in immune thrombocytopenia (ITP) patients in the era of rituximab therapy are unknown. Objectives To assess the risk factors for serious and non-serious infections (respectively, SIs and NSIs) in non-splenectomized adults treated for persistent or chronic primary ITP, including the effect of pneumococcal and influenza vaccines. Patients/Methods The population was the 2009-2012 FAITH cohort (n = 1805), which is the cohort of all incident (newly diagnosed) primary ITP adults treated > 3 months in France built into the national health insurance database (SNIIRAM). SIs were hospitalizations with any infection as the primary diagnosis code. NSIs were identified using out-of-hospital antibiotic dispensing. Cox models were performed. Results Incidence rates were 6.3/100 patient-years (95% confidence interval [CI], 5.4-7.4) for SIs (lower respiratory tract in 42.8% of the cases) and 100.5/100 patient-years (95% CI, 95.0-106.3) for NSIs. In multivariate analyses, increasing age and chronic pulmonary disease were associated with both SI and NSI occurrence. The hazard ratios (HRs) for corticosteroids and rituximab were, respectively, 3.83 (95% CI, 2.76-5.31) and 2.60 (95% CI, 1.67-4.03) for SIs and 2.46 (95% CI, 2.19-2.76) and 1.49 (95% CI, 1.28-1.74) for NSIs. Pneumococcal vaccine showed a protective effect for both SIs and NSIs (0.38 [95% CI, 0.20-0.73] and 0.52 [95% CI, 0.43-0.65], respectively), as did influenza vaccine (0.42 [95% CI, 0.27-0.64] and 0.49 [95% CI, 0.41-0.59], respectively). Conclusions Chronic pulmonary disease, corticosteroids and rituximab are the main risk factors for infections, whereas pneumococcal and influenza vaccines are protective against SIs and NSIs.
引用
- Moulis G, Lapeyre-Mestre M, Palmaro A, et al. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. J Thromb Haemost. 2017. PMID: 28078756. doi:10.1111/jth.13622
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。